© 1999 American Heart Association, Inc.
Original Contribution |
Adenovirus-Mediated Local Expression of Human Tissue Factor Pathway Inhibitor Eliminates Shear Stress–Induced Recurrent Thrombosis in the Injured Carotid Artery of the Rabbit
From the Divisions of Cardiovascular Surgery (T.N., H.Y.) and Cardiology (H.U., N.A., R.K., A.T.), Research Institute of Angiocardiology, Faculty of Medicine, Kyushu University, Fukuoka; First Department of Pathology, Miyazaki Medical College (Y.A.), Miyazaki; and The Chemo-Sero-Therapeutic Research (Y.N., Y.K.), Kumamoto, Japan.
Correspondence to Hikaru Ueno, MD, PhD, Associate Professor of Medicine, Department of Cardiology, Kyushu University School of Medicine, Fukuoka, 812-8582, Japan. E-mail ueno{at}med.kyushu-u.ac.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract—The main cause of acute coronary syndrome may be recurrent thrombosis, which is initiated by the activation of the extrinsic coagulation pathway. Tissue factor (TF) pathway inhibitor (TFPI) efficiently inhibits an early step in this pathway by the formation of a complex with factor VIIa, TF, and factor Xa. We determined whether local TFPI gene transfer can inhibit thrombosis in an injured artery without inducing systemic side effects. Balloon-injured rabbit carotid arteries were infected with an adenoviral vector that expressed either human TFPI (AdCATFPI) or bacterial ß-galactosidase (AdCALacZ). Two to 6 days after gene transfer, thrombosis was induced by the production of constant stenosis of the artery, and blood flow was measured continuously with an electromagnetic flow probe. A cyclic flow variation, which is thought to reflect the recurrent formation and dislodgment of mural thrombi, was observed in all AdCALacZ-infected arteries as well as in saline-infused arteries. In contrast, no cyclic flow variation was detectable in AdCATFPI-transfected arteries, even in the presence of epinephrine (1 µg · kg-1 · min-1 infusion). Prothrombin time, activated partial thromboplastin time, and the ex vivo platelet aggregation induced by either adenosine diphosphate or collagen were unaltered in AdCATFPI-infected rabbits. We found that in vivo TFPI gene transfer into an injured artery completely inhibits the recurrent thrombosis induced by shear stress even in the presence of catecholamine, without affecting systemic coagulation status. Adenovirus-mediated local expression of TFPI may have the potential for the treatment of human thrombosis.
Key Words: inhibitor • thrombosis • blood flow • gene transfer • adenovirus vector
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Adirect cause of acute coronary syndrome is believed to be thrombotic occlusion of an atherosclerotic coronary artery.1 After balloon angioplasty and stent insertion, occlusion by thrombosis still occurs occasionally, despite the use of antithrombotic agents.2 Thus, inhibition of thrombus formation in the damaged artery is vital for the prevention of a lethal outcome. Current approaches against intravascular thrombosis rely on the systemic administration of drugs such as aspirin, heparin, hirudin, tissue plasminogen activator, and a chimeric antibody to the platelet glycoprotein IIb/IIIa integrin.3 Unfortunately, these agents can produce systemic side effects, most notably the induction of bleeding at locations distant from their intended site of action.3 4 Also, the antithrombotic effects of these drugs, such as aspirin, tend to weaken in the presence of catecholamines.5
Activation of the extrinsic coagulation pathway triggered by the binding of plasma protease factor VII/VIIa to the transmembrane protein tissue factor (TF) is considered to be the event that initiates blood coagulation.6 When bound with factor VIIa, TF efficiently converts factors X and IX to their active forms and leads to the generation of thrombin. Intact endothelial cells produce an anti-TF molecule, known as tissue factor pathway inhibitor (TFPI). TFPI directly inhibits the factor Xa and induces a feedback inhibition of the factor VIIa/TF catalytic complex.7 8 Thus, TFPI efficiently inhibits the upstream events in the coagulation pathway at multiple stages and suppresses thrombin formation.7 8
It has been shown repeatedly that adenovirus-mediated gene transfer into the cells of the vascular wall can elicit site-specific production of recombinant protein for a prolonged period of time.9 10 11 If an antithrombotic agent, such as TFPI, could be locally produced in damaged arteries as a result of gene transfer, this could prove to be both more potent and less harmful as a treatment for intravascular thrombosis than the systemic administration of antithrombotic or fibrinolytic drugs.
In the current study with balloon-injured rabbit carotid arteries, we tested whether local expression of TFPI in an injured artery by adenovirus-mediated in vivo gene transfer would effectively inhibit thrombosis. We observed that local expression of TFPI completely eliminated thrombus formation without the induction of any apparent systemic side effects. The inhibition was not affected by the presence of epinephrine. Our results suggest a therapeutic potential for adenovirus-mediated transfer of TFPI in cases of acute coronary syndrome in humans.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Preparation of Adenoviral Vector
Replication-defective E1- and E3- adenoviral vectors that express human TFPI (AdCATFPI), bacterial ß-galactosidase (AdCALacZ),12 13 14 or no exogenous gene (AdCA1w) under a CA promoter (composed of a cytomegalovirus enhancer and chicken ß-actin promoter)15 were prepared by in vitro homologous recombination in 293 cells by the use of the adenovirus DNA-terminal protein complex16 as described previously.12 13 14 The titer of the virus stock was assessed by a plaque-formation assay with the use of 293 cells and expressed as plaque formation units (pfu).
In Vitro TFPI Secretion From Transfected COS Cells
COS cells were infected with AdCATFPI and incubated in growth
medium for 24 hours. Then, the medium was replaced with serum-free
medium and incubated for another24 hours. The amount of TFPI protein in
the medium was measured by a 1-step sandwich ELISA method with human
recombinant TFPI (rhTFPI) as a standard as described
previously.17 The total TFPI antigen level in rabbit
plasma was also measured by this method.18
TFPI activity was measured by a modified prothrombin time (PT) analysis, as described previously.19 The TFPI activity was expressed in terms of the amount of rhTFPI that would show the same activity. The minimum level detected by this assay is 265 ng/mL. The activity was also measured by a 2-stage chromogenic assay.20 The minimum amount of TFPI detected by this method is 5.3 ng/mL. Human recombinant TFPI was prepared from transfected Chinese hamster ovary cells as previously reported.21
In Vivo Gene Transfer Into Injured Arteries
All animals were treated under protocols approved by the animal
care committee of Kyushu University (Fukuoka, Japan). The experiment
was performed in accordance with both the Guidelines for Animal
Experiments in Kyushu University and the Law (No. 105) and Notification
(No. 6) of the Japanese government. Japanese white rabbits (male,
weight 3250±350 g) were anesthetized with 25 mg/kg of sodium
thiamylal and ventilated via a tracheal tube connected to a mechanical
ventilator. After heparinization (1500 U/kg), a segment of the common
carotid artery (
4 cm in length) was isolated with 2 small clips.
Then, the common carotid artery was balloon injured 4 times by use of a
balloon catheter (3F Fogarty, Baxter). After balloon injury, the
isolated segment was filled with 0.2 mL of Ringer's saline that
contained either AdCATFPI or AdCALacZ (there was no fixed order for
AdCATFPI- and AdCALacZ-infection; final titer
1.5x108 pfu) or with this saline alone.
Incubation was allowed to proceed for 30 minutes, then the solution was
retrieved, and blood circulation was restored. The contralateral common
carotid artery was treated according to the same method described
above.
We did not notice any significant or consistent histological differences between arteries subjected to balloon injury followed by infusion with saline and arteries given an injury followed by adenoviral infection as previously reported.12 14 22 It has recently been reported that no inflammation or vascular injury is induced in rabbit carotid arteries, if the titer of adenovirus used is below the inflammatory threshold, <1.6x109 pfu/mL, adenoviral ß-galactosidase expression produces neither vascular injury nor infiltration of polynuclear monocytes (CD18-positive neutrophils).23 The titer we used in this study was 7.5x108 pfu/mL.
In Vivo TFPI Secretion
To measure in vivo TFPI secretion from the AdCATFPI-infected
arteries, segments (2 cm in length) were harvested 3 days after gene
transfer, rinsed, then placed in DMEM with 10% serum for 24 hours at
37°C. Media were assayed for TFPI antigen and activity as described
above. Saline-infused and AdCALacZ-infected arteries were also assayed
as controls.
Recurrent Thrombosis Model
Recurrent formation and dislodgment of thrombi in the
stenotic artery was monitored by the measurement of carotid
blood flow in a slightly-modified Folts model24 (the
constriction was applied 2 to 6 days after endothelial
denudation). Briefly, 2 or 6 days after gene transfer, a constrictor
(0.7 mm in diameter) was placed around the carotid artery: an
50% reduction in diameter, 75% reduction in area, and 55%
reduction in blood flow was generated in both carotid arteries (cf
Table 2
). A flow probe (FG-020T, Nihon Koden) connected to a
flowmeter was set downstream of the stenotic portion of the
carotid artery, and cyclic blood flow variation (CFV) was monitored
continuously. Heart rate and femoral artery pressure were also
monitored. We first measured CFV in the right carotid artery then the
left carotid artery. We confirmed that the order of measurement between
right and left carotid arteries did not affect the outcome.
|
Determination of Ex Vivo Platelet Aggregation, PT, and
Activated Partial Thromboplastin Time
To check platelet function, the platelet aggregation in
response to either ADP or collagen was evaluated ex vivo. Blood (10 mL)
mixed with sodium citrate was centrifuged at 120g
for 20 minutes at room temperature. Either ADP (1 to 20 mmol/L) or
collagen (0.5 to 20 mg/mL) was added to this sample, and platelet
aggregation was measured turbidimetrically by use of a chronolog
aggregometer. PT and activated partial thromboplastin time
(APTT) were measured with an amelung coagulometer (KC-10A, Baxter)
before and after either an AdCATFPI-infection or an administration of
rhTFPI (80 µg/kg).
Statistical Analysis
Values of CFV (count) and carotid blood flow among arteries were
statistically analyzed with ANOVA. One-way ANOVA with repeated
measures was used for the analysis of PT and APTT. A value of
P<0.05 was considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
TFPI Secretion From AdCATFPI-Infected Cells In Vitro
We examined whether AdCATFPI infection can produce biologically active TFPI. COS cells were infected with AdCATFPI at various multiplicities of infection (MOI), then the TFPI in the medium was measured by ELISA. A large quantity of TFPI was detected in the medium from AdCATFPI-infected COS cells, which was the actual amount of MOI-dependent TFPI (Table 1
). We also
examined the TFPI activity by both a chromogenic
method20 and a modified PT method.19 TFPI
activity was increased in a MOI-dependent manner (Table 1). If
the TFPI protein had been truncated, the activity measured by a
modified PT method would be expected to be reduced.25
Thus, the fact that the values measured by the 2 methods were similar
may suggest that most of the TFPI secreted was the full-length form. No
TFPI antigen or its activity was detectable in medium prepared from
AdCALacZ-infected COS cells. These results indicated that a large
quantity of biologically active TFPI can be generated and secreted into
the medium from AdCATFPI-infected cells.
|
In Vivo TFPI Secretion
We next investigated whether active TFPI could be produced in
AdCATFPI-infected rabbit carotid arteries. TFPI antigen and its
activity were measured in 24-hour explant cultures by use of ELISA or a
chromogenic assay, respectively. A considerable amount of
bioactive TFPI was secreted from the AdCATFPI-infected arteries,
although no secretion of TFPI was detectable from either saline-infused
or AdCALacZ-infected arteries (Figure 1).
|
Elimination of Stenosis-Induced Thrombosis in
AdCATFPI-Infected Arteries
We investigated whether the local expression of TFPI would
effectively inhibit stress-induced thrombosis in injured arteries by
use of the Folts model.24 Six days after balloon injury
and gene transfer, we measured CFV, which is thought to reflect
recurrent cycles of thrombus formation and dislodgment.26
There was no significant difference in carotid blood flow before and
immediately after the establishment of stenosis among arteries
infected with either AdCATFPI or AdCALacZ or infused with saline (Table 2
). After stenosis, CFV was
induced in the AdCALacZ-infected and in the saline-infused arteries.
CFV was also induced in the AdCA1w-infected arteries (data not shown).
These results indicate that neither adenoviral infection itself nor
ß-galactosidase expression caused CFV. In contrast, no CFV was
detectable in the AdCATFPI-infected arteries (Figure 2). When epinephrine was
systemically infused at a dose of 1.0 µg ·
kg-1 · min-1 for
30 minutes, a procedure which has been reported to abolish the
inhibitory effect of aspirin on CFV,27
systemic blood pressure and carotid blood flow were both increased, but
no CFV appeared in the AdCATFPI-infected arteries (Figure 3). When we measured CFV 2 days after
injury and gene transfer, similar results were obtained (data not
shown).
|
|
No Significant Changes in PT and APTT in Plasma of
AdCATFPI-Infected Rabbits
To examine the possible systemic effects that result from local
infection with AdCATFPI, the coagulation indexes PT and APTT were
measured before and 6 days after gene transfer, in which TFPI gene
expression should be submaximal. Neither PT nor APTT was altered in the
AdCATFPI-infected rabbits (Figure 4). On
the other hand, in rabbits subjected to the intravenous
injection of rhTFPI (80 µg/kg; with this amount of rhTFPI, CFV was
temporarily attenuated to a large extent), both PT and APTT became
significantly longer than before injection (Figure 4).
|
TFPI concentration in blood was monitored in AdCATFPI-infected rabbits. No TFPI was detectable by our assay system in intact rabbits or in rabbits that were injured and infected with AdLacZ (the antibody against human TFPI we used in the assay did not cross-react with rabbit TFPI). In the plasma of the AdCATFPI-infected rabbits (blood was collected 6 days after gene transfer), a small but significant amount of TFPI (8.2±2.5 ng/mL, mean±SD, n=6) was detectable. Although the amounts of endogenous TFPI in normal rabbits are unknown due to lack of an appropriate assay system, note that the amounts of TFPI in the AdCATFPI-infected rabbits are considerably lower than those detected in normal healthy humans (52.4±9.9 ng/mL, mean±SD, n=30).17 In contrast, a high concentration of TFPI (330±21.8 ng/mL) was detected 1 minute after a bolus injection of rhTFPI (80 µg/kg).
Preserved Platelet Function in AdCATFPI-Infected
Rabbits
Because an inhibition of platelet function can result in an
elimination of CFV,24 platelet function was examined
by use of an ex vivo platelet aggregation assay. The aggregation in
response to either ADP or collagen at various concentrations was
measured before and 6 days after gene transfer.
Platelet-aggregation was not affected in AdCATFPI-infected rabbits
nor in rabbits infused with rhTFPI (80 µg/kg; Figure 5).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The main finding of this study is that local expression of TFPI via adenovirus-mediated single gene transfer achieves a potent (complete) inhibition of shear stress–induced mural thrombosis in injured arteries for a prolonged period of time without alternating the systemic state of coagulation. Thrombin generation and subsequent thrombus formation are critical events that lead to acute occlusion in injured arteries. These responses are initiated by an activation of the extrinsic pathway that results from an encounter between coagulation factors in the blood and TF in the endothelium-stripped arterial wall.28 29 It is known that TF expression in the arterial wall increases rapidly (within hours) after balloon injury.6 29 This event would be expected to be amplified in an atherosclerotic artery, because abundant TF is consistently expressed in the neointima in such vessels.28 It was reported that plasma levels of TF and TFPI were significantly elevated in patients with ischemic heart diseases versus control subjects.30 All this information suggests that an efficient method of inhibiting TF function may also be an efficient way of suppressing thrombosis. To support this hypothesis, an antithrombotic effect caused by systemic infusion of a monoclonal antibody against TF has been reported in stenotic rabbit carotid arteries.31 It has also been reported that an active-site mutated form of factor VIIa efficiently inhibits thrombosis.32 These reports further support the concept that TF exposure plays a critical role in the generation of thrombin and the thrombus and that inhibition of TF activity should therefore effectively suppress the resulting thrombosis. With this background in mind, in the current study, we locally expressed TFPI, a physiological suppresser of TF,7 8 in balloon-injured arteries through adenovirus-mediated in vivo gene transfer. This may have an advantage over the use of a thrombin antagonist, such as hirudin, because TFPI would be expected to suppress any fresh formation of thrombin by inhibition of the very first steps in the extrinsic8 32 and the common coagulation pathways (by a direct inhibition of factor Xa,7 although whether this is true in vivo needs further study).
The rabbit model of thrombosis used in the present study is based on a model developed by Folts et al.27 This model has been used by many investigators to evaluate clot formation in vivo (See Reference 2424 ). CFVs were also observed in humans after angioplasty.33 Histological studies of arteries26 and studies with radiolabeled platelets34 have demonstrated that CFV is a reliable marker for recurrent thrombus formation. In our study, we measured CFV 2 to 6 days after balloon injury and gene transfer, although in the original Folts model, CFV is monitored immediately after endothelial denudation. Balloon injury evokes many responses including de novo TF production,35 proliferation and transformation of smooth muscle cells,36 and accumulation of extracellular matrix, which is a major source of TF expression.37 For that reason, the arteries we used might have been more prothrombotic and possibly more resistant to antithrombosis agents than the arteries used in the original model. We could argue that we tested the inhibitory effect of TFPI gene transfer under more complicated conditions than those created by the original model. In consideration of the above factors, the fact that CFV was completely abolished in the AdCATFPI-treated arteries seems to suggest a potential future clinical application for AdCATFPI. Finally, note that even in the presence of epinephrine, no CFV was generated in AdCATFPI-treated arteries. Because the inhibitory effect of aspirin, which depends on its suppression of platelet function, is lost with epinephrine,5 these results suggest that the inhibitory effect of TFPI does not depend on platelet function. Rather, TFPI may act on the arterial wall.
A major advantage of the local expression of TFPI through in vivo gene
transfer is shown by the fact that no systemic side effects were seen
in our rabbits (Figures 4 and 5). In the search for
effective ways to prevent or treat intravascular thrombosis, many
antithrombotic or profibrinolytic drugs have been administered
systemically. Unfortunately, although some of these drugs exerted a
significant inhibitory effect on thrombosis, such agents
also tended to induce systemic bleeding.3 4 This is an
important factor in the determination of clinical usefulness and
indicates the potential advantage of local gene transfer into an
injured artery. On the other hand, note that with gene transfer, some
time (at least a few hours) will elapse before an amount of protein
large enough to produce meaningful biological effects becomes
available. Brown et al38 have shown that local irrigation
with rTFPI, inhibited platelet aggregation 10 minutes after
arterial intervention in the rabbit carotid arteries,
although it was not demonstrated whether a single irrigation with rTFPI
inhibits the thrombus formation for a long time, such as a week. Our
study demonstrates that TFPI gene transfer into the injured arteries
completely inhibits the shear stress–induced recurrent thrombosis 
6
days after gene transfer even in the presence of
catecholamine. Combined treatment with rhTFPI protein and
TFPI gene transfer should have the advantage that the 2 effects would
complement each other, thus leading to a more complete suppression of
mural thrombosis.
In addition to hirudin gene transfer,39 gene transfer of cyclooxygenase has been efficacious in the augmentation of prostaglandin I2 production, thereby inhibiting thrombosis in the injured porcine carotid artery, although a high titer of virus was required.40 Additional studies are required to determine which of the various antithrombotic molecules is likely to be the best candidate for future antithrombosis gene therapy.
In summary, our study shows that adenovirus-mediated site-specific TFPI gene transfer into injured arteries eliminates shear stress–induced mural thrombosis for a substantial period of time, even in the presence of catecholamine, without inducing apparent systemic side effects. The antithrombosis effect of AdCATFPI infection must be confirmed in animals fed cholesterol, in arteries in which neointima is already formed, and in coronary arteries of larger mammals before this technique is considered a suitable future approach for the treatment of human arterial thrombotic disorders.
|
Acknowledgments |
|---|
This study was supported in part by grant-in-aid for scientific research from the Ministry of Education, Science and Culture of Japan (H.U.), and by a grant from the Takeda Medical Research Foundation (Osaka, Japan; H.U.).
Received January 5, 1999; accepted April 7, 1999.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med. 1992;326:242–250.[Medline] [Order article via Infotrieve]
2.
Williams DO, Braunwald E, Thompson B, Sharaf BL,
Buller CE, Knatterud GL. Results of percutaneous
transluminal coronary angioplasty in unstable angina and
non-Q-wave myocardial infarction: observations from the TIMI IIIB
Trial. Circulation. 1996;94:2749–2755.
3.
Aguirre FV, Topol EJ, Ferguson JJ, Anderson K,
Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G.
Bleeding complications with the chimeric antibody to platelet
glycoprotein IIb/IIIa integrin in patients undergoing
percutaneous coronary intervention: EPIC
Investigators. Circulation. 1995;91:2882–2890.
4. Adgey AA. Bleeding complications with new antithrombotics used in ischaemic heart disease. Haemostasis. 1996;26:237–246.[Medline] [Order article via Infotrieve]
5. Folts JD, Rowe GG, Rao GHR. Problem with aspirin as antithrombotic agent in coronary artery disease. Lancet. 1988;1:937–938.
6. Taubman MB, Fallon JT, Schecter AD, Giesen P, Mendlowitz M, Fyfe BS, Marmur JD, Nemerson Y. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997;78:200–204.[Medline] [Order article via Infotrieve]
7. Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med. 1995;46:103–112.[Medline] [Order article via Infotrieve]
8.
Lindahl AK. Tissue factor pathway
inhibitor: from unknown coagulation inhibitor
to major antithrombotic principle. Cardiovasc Res. 1997;33:286–291.
9.
Schneider MD, French BA. The advent of adenovirus:
gene therapy for cardiovascular disease.
Circulation. 1993;88:1937–1942.
10.
Nabel EG. Gene therapy for
cardiovascular disease. Circulation. 1995;91:541–548.
11.
Baek S, March KL. Gene therapy for restenosis.
Circ Res. 1998;82:295–305.
12.
Ueno H, Li JJ, Tomita H, Yamamoto H, Pan Y, Kanegae Y,
Saito I, Takeshita A. Quantitative analysis of repeat
adenovirus-mediated gene transfer into injured canine femoral arteries.
Arterioscler Thromb Vasc Biol. 1995;15:2246–2253.
13.
Ueno H, Yamamoto H, Ito S, Li JJ, Takeshita A.
Adenovirus-mediated transfer of a dominant-negative H-ras
suppresses neointimal formation in balloon-injured arteries
in vivo. Arterioscler Thromb Vasc Biol. 1997;17:898–904.
14.
Ueno H, Haruno A, Morisaki N, Furuya M, Kangawa K,
Takeshita A, Saito Y. Local expression of C-type
natriuretic peptide markedly suppresses
neointimal formation in rat injured arteries through an
autocrine/paracrine loop. Circulation. 1997;96:2272–2279.
15. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 1991;108:193–199.[Medline] [Order article via Infotrieve]
16.
Miyake S, Makimura M, Kanegae Y, Harada S, Sato Y,
Takamori K, Tokuda C, Saito I. Efficient generation of recombinant
adenoviruses using adenovirus DNA-terminal protein complex and a cosmid
bearing the full-length virus genome. Proc Natl Acad Sci
U S A. 1996;93:1320–1324.
17. Kamikura Y, Wada H, Yamada A, Shimura M, Hiyoyama K, Shiki H, Tanigawa M, Nishikawa H, Yamada N, Isaka N, Nakao T, Kumeda K, Kato H. Increased tissue factor pathway inhibitor in patients with acute myocardial infarction. Am J Hematol. 1997;55:183–187.[Medline] [Order article via Infotrieve]
18. Kamikubo Y, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A. Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 1997;407:116–120.[Medline] [Order article via Infotrieve]
19.
Kamei S, Kamikubo Y, Hamuro T, Fujimoto H, Ishihara M,
Yonemura H, Miyamoto S, Funatsu A, Enjyoji K, Abumiya T. Amino acid
sequence and inhibitory activity of rhesus monkey tissue
factor pathway inhibitor (TFPI): comparison with human
TFPI. J Biochem. 1994;115:708–714.
20. Sandset PM. Chromogenic substrate assay of extrinsic pathway inhibitor: levels in the normal population and relation to cholesterol. Blood Coagul Fibrinolysis. 1991;2:425–433.[Medline] [Order article via Infotrieve]
21. Enjyoji K, Miyata T, Kamikubo Y, Kato H. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site. Biochemistry. 1995;34:5725–5735.[Medline] [Order article via Infotrieve]
22.
Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel
EG, Parmacek MS, Leiden JM. Cytostatic gene therapy for vascular
proliferative disorders with a constitutively active form of the
retinoblastoma gene product. Science. 1995;267:518–522.
23.
Channon KM, Qian H, Youngblood SA, Olmez E, Shetty GA,
Neplioueva V, Blazing MA, George SE. Acute host-mediated
endothelial injury after adenoviral gene transfer in
normal rabbit arteries. Circ Res. 1998;82:1253–1262.
24. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation. 1991;83(suppl): IV3–IV14. Review.
25. Nordfang O, Bjorn SE, Valentin S, Nielsen LS, Wildgoose P, Beck TC, Hedner U. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity. Biochemistry. 1991;30:10371–10376.[Medline] [Order article via Infotrieve]
26.
Strony J, Beaudoin A, Brands D, Adelman B.
Analysis of shear stress and hemodynamic
factors in a model of coronary artery stenosis and
thrombosis. Am J Physiol. 1993;265:H1787–H1796.
27.
Folts JD, Crowell EB Jr, Rowe GG. Platelet
aggregation in partially obstructed vessels and its elimination with
aspirin. Circulation. 1976;54:365–370.
28.
Wilcox JN, Smith KM, Schwartz S, Gordon D. Localization
of tissue factor in the normal vessel wall and in the atherosclerotic
plaque. Proc Natl Acad Sci U S A. 1989;86:2839–2843.
29. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V, Mendlowitz M, Nemerson Y, Taubman MB. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury. J Clin Invest. 1993;91:2253–2259.
30. Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Serneri GGN. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart disease patients. Thromb Haemost. 1998;79:495–499.[Medline] [Order article via Infotrieve]
31.
Pawashe AB, Golino P, Ambrosio G, Migliaccio F, Ragni
M, Pascucci I, Chiariello M, Bach R, Garen A, Konigsberg WK. A
monoclonal antibody against rabbit tissue factor inhibits thrombus
formation in stenotic injured rabbit carotid arteries.
Circ Res. 1994;74:56–63.
32.
Jang Y, Guzman LA, Lincoff AM, Gottsauner-Wolf M,
Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ.
Influence of blockade at specific levels of the coagulation cascade on
restenosis in a rabbit atherosclerotic femoral artery injury
model. Circulation. 1995;92:3041–3050.
33. Anderson HV, Kirkeeide RL, Krishnaswami A, Weigelt LA, Revena M, Weisman HF, Willerson JT. Cyclic flow variations after coronary angioplasty in humans: clinical and angiographic characteristics and elimination with 7E3 monoclonal antiplatelet antibody. J Am Coll Cardiol. 1994;23:1031–1037.[Abstract]
34.
Golino P, Buja LM, Ashton JH, Kulkarni P, Taylor A,
Willerson JT. Effect of thromboxane and
serotonin receptor antagonists on
intracoronary platelet deposition in dogs with
experimentally stenosed coronary arteries.
Circulation. 1982;65:248–255.
35. Taubman MB, Marmur JD, Rosenfield CL, Guha A, Nichtberger S, Nemerson Y. Agonist-mediated tissue factor expression in cultured vascular smooth muscle cells: role of Ca2+ mobilization and protein kinase C activation. J Clin Invest. 1993;91:547–552.
36.
Willerson JT, Yao GK, McNatt J, Benedict CR, Anderson
HV, Golino P, Murphree SS, Buja LM. Frequency and severity of cyclic
flow alternations and platelet aggregation predict the severity of
neointimal proliferation following experimental
coronary stenosis and endothelial
injury. Proc Natl Acad Sci U S A. 1991;88:10624–10628.
37. Hatakeyama K, Asada Y, Marutsuka K, Sato Y, Kamikubo Y, Sumiyoshi A. Localization and activity of tissue factor in human aortic atherosclerotic lesions. Atherosclerosis. 1997;133:213–219.[Medline] [Order article via Infotrieve]
38.
Brown DM, Kania NM, Choi ET, Lantieri LA, Pasia EN, Wun
T-C, Khouri RK. Local irrigation with tissue factor pathway
inhibitor inhibits intimal hyperplasia induced by
arterial interventions. Arch Surg. 1996;131:1086–1090.
39. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury. Nature Med. 1996;2:293–298.[Medline] [Order article via Infotrieve]
40.
Zoldhelyi P, McNatt J, Xu XM, Loose-Mitchell D, Meidell
RS, Clubb FJ Jr, Buja LM, Willerson JT, Wu KK. Prevention of
arterial thrombosis by adenovirus-mediated transfer of
cyclooxygenase gene. Circulation. 1996;93:10–17.
This article has been cited by other articles:
 |
|
 |
|
  Y. Zhao, S. Zhou, and C.-K. Heng Impact of Serum Amyloid A on Tissue Factor and Tissue Factor Pathway Inhibitor Expression and Activity in Endothelial Cells Arterioscler. Thromb. Vasc. Biol., July 1, 2007; 27(7): 1645 - 1650. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-J. Stampfuss, P. Censarek, J. W. Fischer, K. Schror, and A.-A. Weber Rapid Release of Active Tissue Factor From Human Arterial Smooth Muscle Cells Under Flow Conditions Arterioscler. Thromb. Vasc. Biol., May 1, 2006; 26(5): e34 - e37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Steffel, T. F. Luscher, and F. C. Tanner Tissue Factor in Cardiovascular Diseases: Molecular Mechanisms and Clinical Implications Circulation, February 7, 2006; 113(5): 722 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Furukoji, M. Matsumoto, A. Yamashita, H. Yagi, Y. Sakurai, K. Marutsuka, K. Hatakeyama, K. Morishita, Y. Fujimura, S. Tamura, et al. Adenovirus-Mediated Transfer of Human Placental Ectonucleoside Triphosphate Diphosphohydrolase to Vascular Smooth Muscle Cells Suppresses Platelet Aggregation In Vitro and Arterial Thrombus Formation In Vivo Circulation, February 15, 2005; 111(6): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.E. Morange, C. Simon, M.C. Alessi, G. Luc, D. Arveiler, J. Ferrieres, P. Amouyel, A. Evans, P. Ducimetiere, I. Juhan-Vague, et al. Endothelial Cell Markers and the Risk of Coronary Heart Disease: The Prospective Epidemiological Study of Myocardial Infarction (PRIME) Study Circulation, March 23, 2004; 109(11): 1343 - 1348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Yamashita, Y. Asada, H. Sugimura, H. Yamamoto, K. Marutsuka, K. Hatakeyama, S. Tamura, Y. Ikeda, and A. Sumiyoshi Contribution of von Willebrand Factor to Thrombus Formation on Neointima of Rabbit Stenotic Iliac Artery Under High Blood-Flow Velocity Arterioscler. Thromb. Vasc. Biol., June 1, 2003; 23(6): 1105 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yin, C. Yutani, Y. Ikeda, K. Enjyoji, H. Ishibashi-Ueda, S. Yasuda, Y. Tsukamoto, H. Nonogi, Y. Kaneda, and H. Kato Tissue factor pathway inhibitor gene delivery using HVJ-AVE liposomes markedly reduces restenosis in atherosclerotic arteries Cardiovasc Res, December 1, 2002; 56(3): 454 - 463. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-Y. Qian, A. Haruno, Y. Asada, T. Nishida, Y. Saito, T. Matsuda, and H. Ueno Local Expression of C-Type Natriuretic Peptide Suppresses Inflammation, Eliminates Shear Stress-Induced Thrombosis, and Prevents Neointima Formation Through Enhanced Nitric Oxide Production in Rabbit Injured Carotid Arteries Circ. Res., November 29, 2002; 91(11): 1063 - 1069. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. S. Zuckerbraun and E. Tzeng Vascular Gene Therapy: A Reality of the 21st Century Arch Surg, July 1, 2002; 137(7): 854 - 861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Cavusoglu, I. Chen, J. Rappaport, and J. D. Marmur Inhibition of Tissue Factor Gene Induction and Activity Using a Hairpin Ribozyme Circulation, May 14, 2002; 105(19): 2282 - 2287. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Corti, V. Fuster, and J.J. Badimon Strategy for ensuring a better future for the vessel wall Eur. Heart J. Suppl., February 1, 2002; 4(suppl_A): A31 - A41. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Golino, P. Cirillo, P. Calabro', M. Ragni, D. D'Andrea, E. V. Avvedimento, F. Vigorito, N. Corcione, F. Loffredo, and M. Chiariello Expression of exogenous tissue factor pathway inhibitor in vivo suppresses thrombus formation in injured rabbit carotid arteries J. Am. Coll. Cardiol., August 1, 2001; 38(2): 569 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Westrick, P. F. Bodary, Z. Xu, Y.-C. Shen, G. J. Broze, and D. T. Eitzman Deficiency of Tissue Factor Pathway Inhibitor Promotes Atherosclerosis and Thrombosis in Mice Circulation, June 26, 2001; 103(25): 3044 - 3046. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zoldhelyi, Z.-Q. Chen, H. S. Shelat, J. M. McNatt, and J. T. Willerson Local gene transfer of tissue factor pathway inhibitor regulates intimal hyperplasia in atherosclerotic arteries PNAS, March 27, 2001; 98(7): 4078 - 4083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Rauch, J. I. Osende, V. Fuster, J. J. Badimon, Z. Fayad, and J. H. Chesebro Thrombus Formation on Atherosclerotic Plaques: Pathogenesis and Clinical Consequences Ann Intern Med, February 6, 2001; 134(3): 224 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Atsuchi, T. Nishida, K. Marutsuka, Y. Asada, Y. Kamikubo, A. Takeshita, and H. Ueno Combination of a Brief Irrigation With Tissue Factor Pathway Inhibitor (TFPI) and Adenovirus-Mediated Local TFPI Gene Transfer Additively Reduces Neointima Formation in Balloon-Injured Rabbit Carotid Arteries Circulation, January 30, 2001; 103(4): 570 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sinnaeve, O. Varenne, D. Collen, and S. Janssens Gene therapy in the cardiovascular system: an update Cardiovasc Res, December 1, 1999; 44(3): 498 - 506. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Busse and I. Fleming A critical look at cardiovascular translational research Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H1655 - H1660. [Full Text] [PDF]
|
|
|
|
|
|
T. Finkel Thinking Globally, Acting Locally : The Promise of Cardiovascular Gene Therapy Circ. Res., June 25, 1999; 84(12): 1471 - 1472. [Full Text] [PDF]
|
|
|
|
|
|
M. Kubo-Inoue, K. Egashira, M. Usui, M. Takemoto, K. Ohtani, M. Katoh, H. Shimokawa, and A. Takeshita Long-term inhibition of nitric oxide synthesis increases arterial thrombogenecity in rat carotid artery Am J Physiol Heart Circ Physiol, April 1, 2002; 282(4): H1478 - H1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Singh, S. Pan, C. S. Mueske, T. Witt, L. S. Kleppe, T. E. Peterson, A. Slobodova, J.-Y. Chang, N. M. Caplice, and R. D. Simari Role for Tissue Factor Pathway in Murine Model of Vascular Remodeling Circ. Res., July 6, 2001; 89(1): 71 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kato Regulation of Functions of Vascular Wall Cells by Tissue Factor Pathway Inhibitor: Basic and Clinical Aspects Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 539 - 548. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||